79 related articles for article (PubMed ID: 8995644)
1. Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3.
Nieves A; Levy LS; Lenz J
J Virol; 1997 Feb; 71(2):1213-9. PubMed ID: 8995644
[TBL] [Abstract][Full Text] [Related]
2. Replication and pathogenicity of primer binding site mutants of SL3-3 murine leukemia viruses.
Lund AH; Schmidt J; Luz A; Sørensen AB; Duch M; Pedersen FS
J Virol; 1999 Jul; 73(7):6117-22. PubMed ID: 10364369
[TBL] [Abstract][Full Text] [Related]
3. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.
Mansour MR; Abraham BJ; Anders L; Berezovskaya A; Gutierrez A; Durbin AD; Etchin J; Lawton L; Sallan SE; Silverman LB; Loh ML; Hunger SP; Sanda T; Young RA; Look AT
Science; 2014 Dec; 346(6215):1373-7. PubMed ID: 25394790
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of murine T-cell lymphoblastic lymphoma identifies deregulation of S-phase initiating genes.
Dabrowska MJ; Ejegod D; Lassen LB; Johnsen HE; Wabl M; Pedersen FS; Dybkær K
Leuk Res; 2013 Oct; 37(10):1383-90. PubMed ID: 23896059
[TBL] [Abstract][Full Text] [Related]
5. Antisense transcription in gammaretroviruses as a mechanism of insertional activation of host genes.
Rasmussen MH; Ballarín-González B; Liu J; Lassen LB; Füchtbauer A; Füchtbauer EM; Nielsen AL; Pedersen FS
J Virol; 2010 Apr; 84(8):3780-8. PubMed ID: 20130045
[TBL] [Abstract][Full Text] [Related]
6. Loss of MicroRNA targets in the 3' untranslated region as a mechanism of retroviral insertional activation of growth factor independence 1.
Dabrowska MJ; Dybkaer K; Johnsen HE; Wang B; Wabl M; Pedersen FS
J Virol; 2009 Aug; 83(16):8051-61. PubMed ID: 19474094
[TBL] [Abstract][Full Text] [Related]
7. Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element.
Ejegod D; Sørensen KD; Mossbrugger I; Quintanilla-Martinez L; Schmidt J; Pedersen FS
J Virol; 2009 Jan; 83(1):336-46. PubMed ID: 18945767
[TBL] [Abstract][Full Text] [Related]
8. ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer.
Mertz JA; Kobayashi R; Dudley JP
J Virol; 2007 Apr; 81(7):3503-13. PubMed ID: 17229714
[TBL] [Abstract][Full Text] [Related]
9. Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.
Sørensen KD; Quintanilla-Martinez L; Kunder S; Schmidt J; Pedersen FS
J Virol; 2004 Dec; 78(23):13216-31. PubMed ID: 15542674
[TBL] [Abstract][Full Text] [Related]
10. Regulation of FeLV-945 by c-Myb binding and CBP recruitment to the LTR.
Finstad SL; Prabhu S; Rulli KR; Levy LS
Virol J; 2004 Sep; 1():3. PubMed ID: 15507152
[TBL] [Abstract][Full Text] [Related]
11. Genome-based identification of cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas.
Kim R; Trubetskoy A; Suzuki T; Jenkins NA; Copeland NG; Lenz J
J Virol; 2003 Feb; 77(3):2056-62. PubMed ID: 12525640
[TBL] [Abstract][Full Text] [Related]
12. Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus.
Rulli K; Lenz J; Levy LS
J Virol; 2002 Mar; 76(5):2363-74. PubMed ID: 11836414
[TBL] [Abstract][Full Text] [Related]
13. Type B leukemogenic virus has a T-cell-specific enhancer that binds AML-1.
Mertz JA; Mustafa F; Meyers S; Dudley JP
J Virol; 2001 Mar; 75(5):2174-84. PubMed ID: 11160721
[TBL] [Abstract][Full Text] [Related]
14. Tissue distribution and timing of appearance of polytropic envelope recombinants during infection with SL3-3 murine leukemia virus or its weakly pathogenic SL3DeltaMyb5 mutant.
Rulli K; Lobelle-Rich PA; Trubetskoy A; Lenz J; Levy LS
J Virol; 2001 Jan; 75(1):522-6. PubMed ID: 11119621
[TBL] [Abstract][Full Text] [Related]
15. Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.
Ethelberg S; Tzschaschel BD; Luz A; Diaz-Cano SJ; Pedersen FS; Schmidt J
J Virol; 1999 Dec; 73(12):10406-15. PubMed ID: 10559359
[TBL] [Abstract][Full Text] [Related]
16. Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.
Martiney MJ; Rulli K; Beaty R; Levy LS; Lenz J
J Virol; 1999 Sep; 73(9):7599-606. PubMed ID: 10438850
[TBL] [Abstract][Full Text] [Related]
17. Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus.
Martiney MJ; Levy LS; Lenz J
J Virol; 1999 Mar; 73(3):2143-52. PubMed ID: 9971797
[TBL] [Abstract][Full Text] [Related]
18. Sequence-specific and/or stereospecific constraints of the U3 enhancer elements of MCF 247-W are important for pathogenicity.
DiFronzo NL; Holland CA
J Virol; 1999 Jan; 73(1):234-41. PubMed ID: 9847326
[TBL] [Abstract][Full Text] [Related]
19. The secondary structure of the R region of a murine leukemia virus is important for stimulation of long terminal repeat-driven gene expression.
Cupelli L; Okenquist SA; Trubetskoy A; Lenz J
J Virol; 1998 Oct; 72(10):7807-14. PubMed ID: 9733816
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
